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Septins are highly conserved filamentous proteins first characterized in
budding yeast and subsequently identified in must eukaryotes. Septins can
bind and hydrolyze GTP, which is intrinsically related to their formation
of septin hexamers and functional protein interactions. The human septin
family is composed of 14 loci, SEPT1-SEPT14, which encode dozens of
different septin proteins. Their central GTPase and polybasic domain
regions are highly conserved but they diverge in their N-terminus and/or
C-terminus. The mechanism by which the different isoforms are generated
is not yet well understood, but one can hypothesize that the use of different
promoters and/or alternative splicing could give rise to these variants.
Septins perform diverse cellular functions according to tissue expression
and their interacting partners. Functions identified to date include cell
division, chromosome segregation, protein scaffolding, cellular polarity,
motility, membrane dynamics, vesicle trafficking, exocytosis, apoptosis,
and DNA damage response. Their expression is tightly regulated to
maintain proper filament assembly and normal cellular functions.
Alterations of these proteins, by mutation or expression changes, have
been associated with a variety of cancers and neurological diseases. The
association of septins with cancer results from alterations of expression in
solid tumors or translocations in leukemias [mixed lineage leukemia
(MLL)]. Expression changes in septins have also been associated with
neurological conditions such as Alzheimer’s and Parkinson’s disease, as
well as retinopathies, hepatitis C, spermatogenesis and Listeria infection.
Pathogenic mutations of SEPT9 were identified in the autosomal dominant
neurological disorder hereditary neuralgic amyotrophy (HNA).
Human septin research over the past decade has established their
importance in cell biology and human disease. Further functional
characterization of septins is crucial to our understanding of their possible
diagnostic, prognostic, and therapeutic applications.
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Forty years ago, septin’s pioneer researchers may
have never imagined that their discovery of four
novel yeast genes would open the door to a bio-
logically complex world of cytoskeletal GTPases
that were highly relevant to human disease. Septins
were first characterized in Saccharomyces cere-
visiae as a group of cytoskeletal GTP-binding pro-
teins essential for proper cell division. Genetic
screening performed by Hartwell and colleagues
for budding yeast mutants led to the discovery
of the first septin genes, CDC3, CDC10, CDC11
and CDC12, in which temperature-sensitive muta-
tions caused defects in budding morphology and
cell cycle arrest (1). These genes were further
characterized in Saccharomyces pombe in which
mutations led to cytokinesis defects during mito-
sis. Subsequently, septins have been found to be
highly conserved in all eukaryotes except plants,
and many of the loci encode for different variants
and/or protein isoforms (Table 1).
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Table 1. Human septins variants and isoforms per locia
Human septin loci Number of recognized variants/isoforms Variable region(s)
SEPT1 – –
SEPT2 Four transcripts/one isoform 5′-UTR and 3′-UTR
SEPT3 Two isoforms 3′-UTR and C-termini
SEPT4 Three isoforms 5′-UTR and 3′-UTR, N- and C- termini
SEPT5 – –
SEPT6 Four isoforms 3′-UTR, C-termini
SEPT7 Two isoforms Alternative splicing exon 2
SEPT8 Four isoforms 5′-UTR and 3′-UTR, N- and C- termini
SEPT9 Seven transcripts/six isoforms 5′-UTR and 3′-UTR, alternative splicing of 5′ exons
SEPT10 Two isoforms Alternative splicing exon 2
SEPT11 – –




aData gathered from NCBI Reference Sequence (Refseq).
Fig. 1. Phylogenetic tree of the human septin family. A dendrogram tree illustrates the phylogenetic relationship of the human
septin family members as determined by Clustal W analysis [modified from Peterson EA, et al. (2007) Mamm Genome].
Recently, phylogenetic and evolutionary analy-
sis for septins of metazoans showed that all septin
proteins could be clustered into four major sub-
groups (Fig. 1). It has been proposed that the
emergence of these four subgroups occurred before
the divergence of vertebrates and invertebrates and
that septin expansion in number was due to dupli-
cation of pre-existing genes (2). Septin research
has grown impressively, from four genes identi-
fied in budding yeast to 14 core loci identified
in humans to date. The variety of existing septin
isoforms and the diversity of their biological func-
tions in eukaryotic cells are both intriguing and
exciting. Contributions to septin biology over the
last few years include the first crystal structure
of septin oligomers, septin protein interactions,
expression profiles, associations with well-known
signaling pathways and involvement in human dis-
ease. These observations have set the stage for
more exciting experimental strategies to further
understand the role of septins in health and dis-
ease. Many questions regarding septins’ multiple
physiological functions in cells as related to nor-
mal development, health, and human diseases still
remain.
Human septin family conserved domains
The four human septin subgroups are character-
ized by sequence homology and domain compo-
sition (Figs 1 and 2). All human septins share a
highly conserved central region that contains a
polybasic domain and the GTP-binding domain.
The N- and C-terminal regions vary in length and
amino acid composition. They contain a proline-
rich domain and an α-helical coiled-coil domain,
respectively. The relevance of the differences in
the N- and C-termini of some septins and their
isoforms is not completely understood, but these
variations might play a role in their unique cellular
localizations, protein interactions, and biological
functions. While the specific functions of these
domains remain to be fully elucidated, recent
studies have begun to reveal information about
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Fig. 2. General structure of septins. N- and C-termini vary between septin family members and their isoforms. Some septins contain
a proline-rich domain in their amino terminus that is involved in protein interaction. The C-terminus of some septins consists of
a coiled-coil domain predicted to contain an α-helix. The polybasic domain is responsible for the association of septins with the
plasma membrane. The central GTP-binding domain contains conserved motifs G1 (GxxxxGK[S/T]), G3 (DxxG) and G4 (xKxD)
and is implicated in the formation of septin heteroligomers and protein interaction.
the possible roles of these domains, as described
later. Several members of the human septin fam-
ily also contain the less well-studied proline-rich
domain near the N-terminal region. Although there
are no specific studies dedicated to understand-
ing the functional role of the proline-rich domain
of septins, one can hypothesize that this domain
may be essential for protein–protein interactions,
including interaction with proteins containing SH3
domains (3, 4). Preceding the GTPase domain, all
mammalian septins, including human septins, con-
tain a highly conserved polybasic domain respon-
sible for the association of septins with cellular
membranes. Studies of the polybasic domain of
SEPT4 have shown that this domain binds to phos-
phoinositol phosphates (5). The polybasic domain
might mediate the targeting of septins to membrane
domains relevant for their role as diffusion barriers
in yeast and mammalian cells. The Wittinghofer
team studied the human septin complex composed
of SEPT2, SEPT6 and SEPT7 and found that these
three septins form a hexameric complex of two
copies of each septin through a GTP/GDP bound
interface, which is also crucial for the GTPase
activity (6, 7). Future studies of these domains are
necessary for comprehensive insight into septins’
intricate functional roles in mammalian cells.
Septins are widely subjected to functionally
significant post-translational modifications. For
example, sumoylation of yeast septins in G2/M-
arrested cells is well described, and the ubiquitin-
protein ligase (E3) Siz1p is required for yeast
septin sumoylation (8). Sumoylation of mam-
malian septins has not yet been reported. How-
ever, mammalian septins contain multiple phos-
phorylation sites and they can be phosphorylated
by Ser/Thr kinases in post-mitotic neurons (9–11)
and by Aurora B kinase in mitotic cells (12). This
suggests that sumoylation and/or phosphorylation
of septins might modulate conformational changes
that can alter their functional role.
Functional role of septins
Despite the mechanistic differences between bud-
ding yeast and dividing animal cells (13), several
orthologs of yeast septins were first identified
in Caenorhabditis elegans (unc-59 and unc-61),
Drosophila melanogaster (pnut) and mammals
[SEPT2 (Nedd5) and SEPT4(H5)] (14–17). Sim-
ilar to yeast septins, animal septins can form
polymeric actin-associated filaments, hydrolyze
GTP and produce multinucleated cells when
mutated (18, 19). Septins can form microfila-
ments by interacting with each other or with
cytoskeletal and filamentous proteins such as actin,
myosin and tubulin, indicative of their functional
roles in cytokinesis during contractile ring for-
mation, cell morphology changes and dynamic
scaffolds (14, 20–24). Several mammalian septins
have many interacting partners (Table 2) and form
complexes between family members to create fil-
aments important in different cellular functions.
One can speculate that some of the diverse func-
tional roles of mammalian septins are intrinsically
related to their physical interactions, which might
explain how one septin can have multiple functions
in different tissues and at different times during
cell cycle and development.
In addition to their roles in cytokinesis, mam-
malian septins have been associated with other
distinct cellular processes including vesicle traf-
ficking, cell polarity, cytoskeletal dynamics, apop-
tosis, neurodegeneration and oncogenesis. The
diversity and complexity of these septin-associated
functions is not well understood, but it is believed
that a wide range of hetero-oligomeric septin
complexes are major players in these cellular
processes. For example, SEPT4/ARTS, an alter-
native transcript of SEPT4, is translocated from
the mitochondrion to the nucleus upon expo-
sure to the apoptotic agent transforming growth
factor-β (TGF-β), possibly providing a mechanistic
link between cell division and cell death (25–27).
Recent data indicate that several septins, includ-
ing SEPT2, 4, 6 and 7, coprecipitate with the
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Table 2. Representative interacting partners and functional roles of mammalian septins
Complexes Putative functions Implicated septin domain References
SEPT1/Aurora B Chromosome segregation,
cytokinesis
Not determined 12
SEPT2/F-actin Cytokinesis GTP binding 14
SEPT2/5/6/anillin Cytokinesis Not determined 105
SEPT2/6/7 Filament formation C- and N- termini 6
SEPT2/GLAST Neurotransmitter release Not determined 56
SEPT2/myosin II Cytokinesis Not determined 106
SEPT2/6/CENP-E Chromosome segregation Not determined 37
SEPT2/6/7/MAP4 Microtubule stability Not determined 22
SEPT2/4/7/Sec6/8 Vesicle trafficking Not determined 30
SEPT3/5/7 Neuronal biology Not determined 107
SEPT4/5/8 Vesicle targeting/exocytosis N- and C- termini 35
SEPT4/8 Platelet biology Not determined 32
SEPT5/Parkin Parkinson’s pathogenesis Not determined 50
SEPT5/11 Exocytosis in endothelial cells GTP binding and C-terminal 33
SEPT5/SNARE complex Vesicle targeting/exocytosis GTP binding and C-terminal 28
SEPT6/12 Filament formation Not determined 108
SEPT7/9/11/actin Filament formation N-terminal 109
SEPT7/CENP-E Chromosome segregation Not determined 48
SEPT8/Vamp2 Snare complex formation,
neurotransmitter release
Not determined 55
SEPT9/actin Stress fiber Not determined 110, 20
SEPT9/SA-RhoGEF/actin Rho signaling N-terminal 110
SEPT9/HIF-1 Cell proliferation, angiogenesis,
prostate cancer
N-terminus GTP binding 72, 96
SEPT9/JNK Cell proliferation, breast cancer GTP binding 100
SEPT9/tubulins Filament formation, microtubules,
spindle formation
GTP binding 20, 23, 24
SEPT11/12 Filament formation Not determined 111
SEPT14/SEPT1-7/9/11-12 Testicular biology Not determined 47
mammalian sec6/8 complex, suggesting an associ-
ation of septins with membrane dynamics and vesi-
cle trafficking (28–31). In addition, septins have
been implicated in platelet function (SEPT4, 5 and
8) (32–35), cardiac myocyte development (36),
chromosome dynamics (SEPT2) (37), cell polar-
ity, motility and microtubule dynamics (SEPT9
and others) (20, 22–24, 38).
In a very elegant study, Kremer et al. showed
that a complex of septin proteins (SEPT2, 6 and
7) interacts with SOCS7, which is necessary to
retain SOCS7 and non-catalytic region of tyrosine
kinase adaptor protein (NCK) in the cytoplasm
at a steady state to regulate actin organization
and the DNA damage response. The SOCS7/NCK
complex accumulates in the nucleus to activate
CHK2 and p53-mediated cell cycle arrest upon
DNA damage. This action is potentiated by the
depletion of the septin complex by siRNA. The
spatial distribution of NCK as mediated by the
septin complex is important in the reorganization
of the actin cytoskeleton, cell polarity and the
DNA damage response. One can predict that in
vivo the distribution of septins in the cytoplasm
is an important mechanism that regulates the
localization of many proteins and their site of
action in the cell (39).
SEPT2 and SEPT11 are required for phago-
some formation, which is important for cell mem-
brane dynamics (31). SEPT2 is also required for
epithelial cell polarity by associating with tubulin
networks and facilitating vesicle transport by pre-
venting polyGlu microtubule tracts from binding to
MAP4 (38). SEPT2 and SEPT11 are modulators
of InlB-mediated invasion by Listeria monocyto-
genes. SEPT2 is essential for the entry of Liste-
ria to the cells, but SEPT11 expression restricts
the efficacy of Listeria invasion (44–46). SEPT12
has been implicated in mammalian spermatogene-
sis (40, 41). In addition, SEPT4 and SEPT7 serve
as diagnostic markers for human male asthono-
zoospermia, because healthy individuals show
septin expression in the annuli of spermatozoa
while infertile patients do not (42). Ihara et al.
showed that the expression of murine Sept4 is
important for the cortical organization required
for morphology and motility of the sperm flagel-
lum (43). Overall, these findings show the diverse
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roles of septins despite their high structural con-
servation.
Most recently, SEPT14, a novel testis-specific
septin was identified and characterized as the
newest member of the human septin family. This
septin was identified in an effort to find novel
interactors of SEPT9 isoforms using a yeast-two
hybrid system. SEPT14 maps to 7p11.2 in humans
and includes a conserved GTPase domain and a
carboxy-terminus coil-coiled domain characteristic
of other septins. SEPT14 was found to interact
with 10 other members of the human septins and
localized with actin stress fibers, a general feature
of septin filaments. Expression analyses in many
fetal, adult and cancer tissues showed that SEPT14
expression is limited to the normal testes by
Northern blot and reverse transcription-polymerase
chain reaction (RT-PCR). Interestingly, SEPT14
expression was negative when tested in cancer cell
lines isolated from testis (47).
Septins as microtubule-associated proteins
Several studies suggest that septins might be
involved in microtubule dynamics and chromo-
some segregation. Two groups showed that mam-
malian SEPT2 and SEPT7 may form a mitotic
scaffold for centromere protein E (CENP-E) and
other effectors to coordinate chromosome seg-
regation and cytokinesis (37, 48). Kremer et al.
proposed a novel molecular function for septins
in mammalian cells through the modulation of
microtubule dynamics via an interaction with
MAP4 (22). Looking specifically at SEPT9 iso-
forms, SEPT9 v1 MLL septin-like fusion gene
variant A (MSFA) was found to localize specif-
ically with microtubules. This localization was
required for the completion of cytokinesis and it
could be disrupted by nocodazole treatment (24).
Interaction of SEPT9 v1 with microtubule net-
works was found to be essential for septin filament
formation (23). We propose that there is a tight
regulation between tubulin filaments, microtubules
and septins filaments. How this regulation is medi-
ated, and what other proteins are involved remains
unclear. Fluorescence microscopy and further
characterization of protein interactions might give
better insight into septin–tubulin interaction and
its regulation of chromosome segregation during
mitosis.
Septins and neurological disorders
Possible roles for septins in neurological disorders
have emerged based on the brain-specific expres-
sion of some septins (Table 3). SEPT2/NEDD5,
SEPT1/DIFF6 and SEPT4/H5 have been found
to associate with Alzheimer-specific neurofibril-
lary tangles (5, 49). The SEPT5/cell division
control-related protein (CDCREL)-1 interaction
with Parkin, a pathogenic protein in Parkinson’s
disease (50, 51), provides evidence for the involve-
ment of another subset of septins in neuronal
development and disease. SEPT4 has also been
implicated in brain pathogenesis by its association
with cytoplasmic inclusions in Parkinson’s disease
and other synocleinopathies (52). The SEPT3/5/7
complex was identified in the mammalian brain
and SEPT3 specifically is developmentally regu-
lated and enriched in presynaptic nerve terminals,
suggesting a role for these septins in neuronal biol-
ogy (53, 54). SEPT2 and SEPT8 are associated
with neurotransmitter release due to their interac-
tion with the glutamate transporter (Glast) and the
synaptic vesicle protein synaptobrevin 2 (Vamp2),
respectively (55, 56). Other septin complexes have
been associated with myelin formation in the
peripheral nervous system (57). Recently, SEPT9
point mutations and a duplication within the gene
have been identified in patients with the auto-
somal dominant neuropathy hereditary neuralgic
amyotrophy (HNA) (58–60), further supporting a
role for septins in neurological disease. The mech-
anism by which these mutations are pathogenic in
HNA is still not fully elucidated, but McDade et al.
showed that isoforms v4 and v4* have distinct 5′
ends encoded by exons where germline mutations
of HNA are found. The two mRNAs are trans-
lated with different efficiencies and cellular stress
can alter this pattern (61). These mutations dramat-
ically enhance the translational efficiency of the
v4 variant, leading to elevated SEPT9 v4 protein
under hypoxic conditions (61). These data provide
mechanistic insight into the effect of HNA muta-
tions on fine control of SEPT9 v4 protein and
its regulation under physiologically relevant con-
ditions. The data are consistent with the episodic
and stress-induced nature of the clinical features
of HNA (61).
Septins in cancer
The first evidence that septins may contribute to
neoplasia occurred with the discovery of septin
SEPT5/CDCREL-1 as a carboxy-terminus fusion
partner with mixed lineage leukemia (MLL) in
an acute myeloid leukemia (AML) patient with
a t(11;22)(q23;q11.2) translocation (62). Subse-
quently, SEPT9/MSF, SEPT6, SEPT2, and SEPT11
were also identified as fusion partners with
MLL in human leukemic cells (63–66). MLL,
the human homolog of Drosophila trithorax, is a
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Table 3. Characteristics of human septin loci and disease associations
Human septin Alternative names
Human
chromosome
location Expression Disease associations
SEPT1 DIFF6 16p11.1 Brain, lymphocytes,
others
Alzheimer’s disease, leukemia, lymphoma
SEPT2 NEDD5, DIFF6 2q37 Brain, lymphocytes,
others
Brain, liver and renal cancer, Von
Hippel-Lindau syndrome, Alzheimer’s
disease, Shigella and Listeria infections
SEPT3 SEP3, G-SEPTIN 22q13.2 Brain-specific Brain cancer, Alzheimer’s disease
SEPT4 ARTS, H5, PNUTL2,
BRADEION, SEP4
17q22 Brain, testes, eye,
lymphocytes
Alzheimer’s disease, skin, urogenital and
colon cancer, leukemia, male infertility
(spermatogenesis defect)
SEPT5 CDCREL-1, PNUTL1 22q11.21 Brain, eye, platelets Leukemia, Parkinson’s disease,
schizophrenia, pancreatic cancer
SEPT6 SEP2, KIAA0128 Xq24 Ubiquitous Schizophrenia, leukemia, hepatitis C
SEPT7 CDC10 7q36.1 Brain, testes Nervous system cancers, male infertility
(spermatogenesis defect)
SEPT8 KIAA0202 5q31 Brain, retina and others Retinal degeneration
SEPT9 MSF, PNUTL4, AF17Q25,
OvBrSEPT, SINT1,
KIAA0991
17q25 Ubiquitous Hereditary neuralgic amyotrophy, leukemia,
breast, ovarian and colorectal cancers,
head and neck cancers, classical
Hodgkin lymphoma, Shigella and Listeria
infections
SEPT10 SEPT1-like 2q13 Ubiquitous –
SEPT11 FLI10849 4q21.1 Ubiquitous Schizophrenia, bipolar disorder, leukemia,
Shigella and Listeria infections
SEPT12 FLI25410 16p13.3 Lymphocytes, testes Male infertility (spermatogenesis defect)
SEPT13 – 7p13 Ubiquitous –
SEPT14 – 7q11 Testes –
common translocation partner in leukemias with
more than 80 rearrangements with 50 fusion
partners identified (67). The well-characterized
MLL fusion products produce in-frame translated
chimeric proteins associated with phenotypic dis-
ease variability such as leukemia type and prognos-
tic outcome. These carboxy partners, in addition
to MLL, appear to be essential contributors to the
pathogenesis of leukemia (68).
Five human septins have also been implicated
in other types of cancer including SEPT2, SEPT3,
SEPT4, SEPT5 and SEPT9 (25, 69, 70). In fact,
SEPT4 acts as a tumor suppressor in leukemias and
solid tumors. The SEPT4 gene promotes apopto-
sis, and is lost in 70% of leukemia patients (26), in
addition to being associated with inhibition of col-
orectal cancer tumorigenesis (71). SEPT9 seems to
be important not only in leukemias but also in solid
tumor cancers (72–77). SEPT2 and SEPT3 were
abundantly expressed in several brain tumors and
brain tumor cell lines, suggesting that these fam-
ily members are potential oncogenes (70). SEPT2
phosphorylation by casein kinase 2 was found to
be important for hepatoma carcinoma cell pro-
liferation (78). In addition, SEPT2 is the only
human septin that has been associated with a spe-
cific human cancer predisposition syndrome, Von
Hippel-Lindau (VHL). VHL is an autosomal dom-
inant genetic condition characterized by heman-
gioblastomas in different tissues and renal cell
carcinoma. Increased SEPT2 expression is a com-
mon event in renal cell carcinomas (78, 79). A pro-
teomic study by Craven et al. showed that SEPT2
was downregulated upon expression of VHL in the
UMRC2 renal cell carcinoma line. This suggests
that SEPT2 is subject to either direct or indirect
VHL regulation (78, 79).
Overall, these studies show that human septins
are important in many cellular and molecular
functions, as summarized in Fig. 3. It seems that
their expression needs to be highly regulated
and the dynamics with their interaction partners
are crucial for their function as either scaffolds
for cytoskeletal proteins or signaling GTPases.
Mutations or altered expression of these genes
can arise by multiple mechanisms that are not
well understood. Many septins are strikingly
associated with multiple human diseases, primarily
cancers and neurological disorders (Table 3 and
Fig. 3).
516
Conquering the complex world of human septins
Fig. 3. Human septins in health and disease. Human septins are involved in multiple tissue and cellular phenotypes. Alterations
in their expression or gene mutations affect these phenotypes, which are mechanistically important in the pathogenesis of many
diseases such as neurological diseases and cancer.
Human SEPT9 locus
SEPT9, with demonstrated roles in both cancer
and neurological disease, provides an illustration
of the diversity of human septin loci. Human
SEPT9 became of great interest to the septin
scientific community after it was found to be
an MLL translocation partner in leukemia (66).
Subsequently, SEPT9 was mapped to chromo-
some 17q25, a region linked to breast and ovar-
ian cancers, by positional cloning to a region of
allelic imbalance in breast and ovarian cancers (74,
80–82). This suggested that alterations of this
novel septin gene may be important not only in
leukemia but also in breast and ovarian cancers.
Afterward, it was shown that the SEPT9 locus
gives rise to multiple alternative transcripts encod-
ing at least seven annotated isoforms (SEPT9 v1-
SEPT9 v7) (74). The SEPT9 locus contains 13
exons and shows high variability at the 5′ and 3′
ends by either alternative splicing of exons or dif-
ferent transcription start sites. The variable exons
1–3 and 12–13 encode alternative translational
start and stop sequences and are spliced onto a
core of eight coding exons (Fig. 4) (74). These
isoforms maintain the general structure of septins
with a highly conserved central region containing
the polybasic domain and GTP-binding domain
(Fig. 2). They vary in the 5′- and 3′-UTRs and
at the N- and C-terminus of the protein. Inter-
estingly, the SEPT9 v4 and SEPT9 v4* isoforms
encode for the exact same protein, but they dif-
fer at their 5′-UTRs, suggesting that these tran-
scripts might be differentially regulated in time
or tissue of expression (73, 76, 77). SEPT9 v1
and SEPT9 v3, the longest transcripts, are highly
similar except for 25 distinct amino acids at the
N-terminus of SEPT9 v1. The biological reason
for the presence of multiple SEPT9 transcripts
is still not elucidated, but many studies, includ-
ing expression analyses, show that these isoforms
are differentially expressed and may have distinct
functional roles in mammalian cells.
SEPT9 is widely expressed based on ubiquitous
adult and fetal transcript expression, although indi-
vidual isoforms may have tissue-specific expres-
sion (74). The cellular localization of SEPT9
isoforms is largely cytoplasmic in interphase cells,
but the SEPT9 v1 isoform has a bipartite nuclear
localization signal that may direct the shuttling
of SEPT9 v1 between the nucleus and the cyto-
plasm. In mitotic cells, SEPT9 exhibits a punc-
tate staining pattern located between the separating
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Fig. 4. SEPT9 genomic structure. Genomic structure of SEPT9 alternatively spliced transcripts and variants. SEPT9 exhibits 5′
and 3′ alternative spliced and variable exons and is composed of 13 exons in total. Gray boxes indicate common exons and colored
boxes indicate variant-specific exons, all drawn to scale. Transcriptional start sites are indicated by (*) and the end of each transcript
by (**). The variable exons (colored boxes) encode different translational start (arrow) and stop (⊗) sequences and are spliced into
a core of common coding exons shared between variants (gray boxes).
chromosomes and at the cleavage furrow during
telophase (24). SEPT9 v1 is localized to micro-
tubule networks in interphase cells and in mitotic
cells it is localized at the mitotic spindle and the
bundle of microtubules at the midzone (23). Both
studies showed that when SEPT9 is ablated, cells
become binucleated, suggesting a role for SEPT9
in cell division via interaction with components of
the cytoskeleton such as tubulins.
Since they were discovered, septins had been
characterized as cytoskeletal GTPases important
in cell division. Mutations of this family of
genes in yeast lead to budding defects, cell cycle
arrest and cytokinesis defects. In mammals, sev-
eral septins (e.g. SEPT2, SEPT5, SEPT7) also
have been implicated in mitosis, specifically in
chromosome segregation dynamics and cytoki-
nesis (Table 2). SEPT9 is not an exception. Its
localization to microtubules, the cleavage fur-
row and midbody at different stages in mitosis
suggests a possible specific role of SEPT9 iso-
forms in chromosome segregation and/or com-
pletion of cell division by affecting the mitotic
spindle assembly, disassembly or dynamics and the
cytokinesis process (Fig. 5).
Intricate human SEPT9 nomenclature
Human septin nomenclature has evolved on the
past decade as illustrated by many alternative
names as shown in Table 3, making the septin
literature difficult to reconcile. SEPT9 is no excep-
tion, as it was originally called MLL septin-like
fusion (MSF) due to the fact that it was identi-
fied as a fusion partner of MLL in leukemias (66).
In 2002, a committee of septin researchers devel-
oped an official nomenclature system for SEPT9
transcripts (83). This new name was derived from
the functional role of these genes in septae for-
mation in yeast. Some research groups published
with the old nomenclature while others used
their own versions, making progress in SEPT9
research hard to reconcile. New nomenclature was
established by the National Center for Biotech-
nology Information (NCBI) and HUGO Gene
Nomenclature Committee (HGNC), but it has yet
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Fig. 5. SEPT9 functional role in mitosis. Diagram showing the phases in mitosis in which SEPT9 expression is present. SEPT9
is localized to the microtubules at the midzone during anaphase and at the cleavage furrow in telophase. Its particular localization
during mitosis suggests a role in chromosome segregation and cytokinesis.
to be universally accepted by the septin commu-
nity. These nomenclature changes are depicted in
Table 4 by group and year. Throughout this review
the nomenclature utilized was established in 2005
by Scott et al. and endorsed at the 2009 Interna-
tional Septin Meeting (76).
SEPT9 as a translocation partner of MLL in
leukemia
Originally, SEPT9/MSF was identified as part
of a fusion protein with the myeloid/lymphoid
leukemia gene (MLL) in a therapy-induced acute
myeloid leukemia (t-AML) patient with a t(11;17)
(q23;q25) rearrangement and was named MSF (66).
The translocation codes for an in-frame tran-
script joining the 5′ of MLL through exon 5 to
SEPT9 at the start of exon 3 through the 3′
terminus. A reciprocal transcript was amplified
in one patient joining the 5′ of MSF through
exons 1-7 of MLL but was out of frame (66,
84). The fusion protein was composed of the
amino protein terminus of MLL, including the
nuclear localization signal, the A-T hook DNA
binding domain, and the DNA methyltransferase-
like DNA binding domain, and a carboxy ter-
minus of SEPT9 v1, including the proline-rich
domain, the polybasic and GTPase domains. Lost
from the carboxy terminus of MLL is the PHD
zinc finger protein–protein interaction domain and
the SET domain thought to regulate gene expres-
sion through chromatin remodeling (66, 84). It has
been suggested that MLL is the sole clinical cause
in leukemias with 11q23 rearrangements as it is
fused to a wide variety of other genes. However,
all of the well-characterized MLL fusion prod-
ucts produce in-frame translated chimeric proteins
associated with phenotypic disease variability
such as leukemia type and prognostic outcome,
which provide further evidence that proteins at
the varying reciprocally translocated chromosomes
are essential contributors to the pathogenesis
of leukemia (67, 68, 85). Thus, speculation on
the contributions of MLL-SEPT9 fusion protein
expression to haematopoetic cellular transforma-
tion would include potential mislocalization of
SEPT9/MSF from the cytoplasm to the nucleus,
aberrant expression of MLL target proteins and
altered activation of MSF GTPase signaling path-
ways. This suggests that these carboxy partners,
in addition to MLL, are essential contributors to
the pathogenesis of leukemia (68) and implicates
septin family members in oncogenesis (85).
SEPT9 model of oncogenesis in solid tumors
A compelling example of the role of septins in the
oncogenesis of solid tumors was the identification
of the MSF/SEPT9 murine ortholog Sint1/Sept9
at a provirus insertion site in SL3-3 murine
leukemia virus (MLV)-induced lymphomas (86),
which demonstrated that this septin locus is a
site for oncogenic integration. SEPT9 also maps
to a region of allelic imbalance at chromosome
17q25.3 in breast cancer (74) and sporadic ovar-
ian cancer (82). In addition, there is a differential
expression of SEPT9 isoforms in tumors of various
tissues (21, 77, 87, 88). SEPT9 has been charac-
terized as a candidate gene in head and neck squa-
mous cell carcinomas by a genome-wide screen
for methylated genes (89, 90). SEPT9 was also
identified as a possible candidate gene for clas-
sical Hodgkin lymphoma (cHL) (91). Circulating














































































































































































































































































































































































































































































































































































identified as a valuable biomarker for minimally
invasive detection of colorectal cancer. This led to
the development of a new methylation (m)SEPT9
assay that may prove useful in clinical research for
the detection of invasive colorectal cancer with a
simple blood test from patients (92–94).
Finally, an isoform of SEPT9, SEPT9 v1, might
be important as a biomarker for therapeutic resis-
tance of many cancers to microtubule disrupting
agents. SEPT9 v1 expression was strongly corre-
lated with susceptibility of a wide range of cancer
cells to drugs such as paclitaxel (95). In general,
cancer cells with high SEPT9 v1 expression were
more resistant to these drugs (95).
SEPT9 isoforms have been associated with
signaling pathways relevant to oncogenesis. For
example, SEPT9 v1 interacts with hypoxia
inducible factor-1-alpha (HIF-1-α) preventing its
ubiquitination and degradation, thereby activat-
ing HIF downstream survival genes to promote
tumor progression and angiogenesis in prostate
cancer cells (72). Also, a new study showed that
SEPT9 upregulates HIF-1 by preventing Rack1-
mediated degradation in an oxygen-independent
manner (96). In addition, a gene expression pro-
file of prostate cancer showed that SEPT9 was
overexpressed in tumors with chromosomal fusion
between androgen-regulated transmembrane pro-
tease serine 2 (TMPRSS2) and v-ets erythroblasto-
sis virus E26 oncogene (ERG). This fusion is asso-
ciated with a more aggressive clinical phenotype
and tumors with TMPRSS2-ERG are regulated by
a estrogen-dependent signaling and are considered
a distinct molecular subclass (97). The SEPT9 v3
isoform binds SA-RhoGEF, functioning as a scaf-
fold to keep it in an inactive state, thereby inhibit-
ing SA-RhoGEF-mediated Rho activation (98, 99).
This finding was crucial for the study of septins in
cancer because it provided a direct link between
septins and signaling proteins involved in cellu-
lar functions such as actin cytoskeletal organiza-
tion, transcriptional activation, tumor invasion, cell
morphology, cell motility and cytokinesis.
SEPT9 expression is also altered in many types
of cancers including head and neck tumors, ovar-
ian, prostate, and breast cancers and it is over-
expressed in a mouse mammary tumor virus
(MMTV) mouse model of mammary tumorigen-
esis (20, 72–76, 86, 92). Most recently, Gonza-
lez et al. showed that preferential expression of
SEPT9 v1 in human mammary epithelial cells pro-
motes pro-oncogenic phenotypes. Briefly, ectopic
expression of SEPT9 v1 using retroviral con-
structs in two immortalized human mammary
epithelial cells, MCF10A and HPV 4-12, increases
cell proliferation, decreases apoptotic response and
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enhances motility and invasiveness, in addition to
present a reminiscent of epithelial to mesenchy-
mal transition (EMT), all hallmarks of oncogenic
transformation in epithelial tissues. In addition,
knockdown of SEPT9, and specifically SEPT9 v1,
via RNA interference assays in two cancer cell
lines with high endogenous levels of SEPT9 v1
(MDA-MB-231 and BT-549) complemented the
observations made in the expression model by
rescuing tumorigenic phenotypes. Another strik-
ing phenotype found was that high SEPT9 v1
expression disrupts proper formation of tubulin
microfilaments in interphase cells and increases
aneuploidy. This study provides compelling evi-
dence that SEPT9 v1 could drive malignant pro-
gression in mammary epithelial cells (20). Another
study also by Gonzalez et al. demonstrated that
upregulation of SEPT9 v1 might increase prolifer-
ation rates of mammary epithelial cells by stabiliz-
ing c-Jun-N-terminal kinase (JNK) proteins, which
are involved in cell proliferation and cell cycle pro-
gression. High SEPT9 v1 expression also showed
to increase JNK kinase activity and the transcrip-
tional activation of JNK target genes important in
cell cycle progression, including cyclin D1 (100).
As a result of these studies, SEPT9 is now
accepted as a novel cancer-associated protein and
is emerging as a potential biomarker for diagnosis
and chemotherapeutic response in some epithelial
cancers.
Conclusion
Since septins were discovered almost 40 years ago,
septin research has grown impressively, from four
genes identified in budding yeast in the mid-1970s
to 14 members identified in humans today. In
yeast, septins were primarily described as filamen-
tous proteins necessary for budding morphology
and cell cycle progression by possibly interacting
with cytoskeleton components. The variety of
septin isoforms and the significant diversity of
their functions in eukaryotic cells have proven to
be intriguing and exciting. Studies of mammalian
septins have been primarily focused on their asso-
ciation with cancer and neurological diseases.
However, many other interesting functions are
coming to light such as the role of certain septins
in bacterial infection (44–46), angiogenesis (72),
spermatogenesis (40–43, 101), retinal degenera-
tion (102, 103), platelet release reaction (32–35,
104), and beyond. Still, questions related to their
normal function in cells and to their implication
in human diseases are still puzzling. Major funda-
mental questions still need to be studied includ-
ing but not limited to: which factors regulate the
tissue-specific and temporal-specific expression of
these proteins?, why do human cells need the pres-
ence of 14 distinct septins?, or which molecular
and/or cellular alterations dictate the involvement
of each specific septin in human diseases? Still,
many of the contributions in septin biology in the
last years including the first crystal structure of
septin oligomers, additional protein interactions,
expression profiles and associations with signaling
pathways and human diseases have set the path
to more exciting experimental strategies to under-
stand further their role in sickness and in health.
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